ANALYST-UPGRADE filed
Canaccord Genuity initiates coverage on AbbVie (ABBV) with a Buy rating and $262 price target, implying 28.6% upside from the current $203.71. The firm’s accuracy is 47% (722/1538), below the 57% average among 15 tracked firms. Consensus is overwhelmingly bullish: 28 of 29 analysts rate ABBV Buy or equivalent (97% Buy-rated), with a mean PT of $249. EPS estimates are declining: 30-day revisions show 7 down, 0 up for current year. Earnings due in 3 days. Insider selling totaled $2.57M in March. Institutional activity mixed: Norges Bank exited, Renaissance Technologies trimmed. Short ratio at 57.1%. Contrarian call from a below-average accuracy firm into weakening EPS trends and negative institutional flows limits signal strength.